Related Experiment Videos
Tumor's other immune targets: dendritic cells
C Esche1, A Lokshin, G V Shurin
1Biologic Therapeutics Program, University of Pittsburgh Cancer Institute, Pennsylvania 15213, USA.
Journal of Leukocyte Biology
|August 17, 1999
Summary
Tumors induce apoptosis in dendritic cells (DC) via tumor-derived factors, representing a novel immune evasion strategy. Protecting these crucial immune cells from tumor-induced death could enhance cancer immunotherapies.
Area of Science:
- Immunology
- Cancer Biology
- Cell Death
Background:
- Tumors evade immune recognition partly through T cell apoptosis.
- Dendritic cells (DCs) are critical for initiating anti-tumor immune responses.
- Understanding DC apoptosis mechanisms is key to overcoming tumor immune evasion.
Purpose of the Study:
- To investigate if tumors induce apoptosis in dendritic cells (DCs).
- To elucidate the mechanisms and in vivo relevance of tumor-induced DC apoptosis.
- To explore the therapeutic implications of protecting DCs from apoptosis.
Main Methods:
- Co-culture of murine/human DCs with tumor cell lines.
- Assessment of DC apoptosis using morphological analysis, JAM assay, TUNEL, Annexin V binding, and DNA fragmentation.
- Analysis of Bcl-2 and Bax expression.
- In vivo confirmation via double staining of tumor tissues and TUNEL assay on isolated DCs.
Main Results:
- Tumor-derived factors induce apoptosis in DCs in a time- and dose-dependent manner.
- Tumor-induced DC apoptosis involves regulation of Bcl-2 and Bax expression.
- DCs within tumor tissues exhibit significantly higher apoptosis rates in vivo compared to splenic DCs.
Conclusions:
- Tumors actively induce apoptosis in dendritic cells as a mechanism of immune evasion.
- This tumor-induced DC apoptosis occurs in vivo and is mediated by specific molecular pathways.
- Strategies to protect DCs from apoptosis may improve DC-based cancer immunotherapies.